Submit Release

EIN Presswire is celebrating 30 years! Follow us on Substack for customer insights, interviews, and more!

World Media Directory · RSS · Email Newsletters

There were 1,699 press releases posted in the last 24 hours and 434,633 in the last 365 days.

Press Releases on July 21, 2023

1,102 Press Releases

Published on July 21, 2023 - 12:30 GMT

Antiviral Drugs Market to Reach a Staggering US$ 89.68 Billion Value by 2033, Driven by Innovative Strategies – Future Market ...

NEWARK, Del, July 21, 2023 (GLOBE NEWSWIRE) -- The global Antiviral Drugs Market has experienced a remarkable surge in recent years, driven by mounting global health concerns and the urgent need for effective treatments against viral infections. The market …

Distribution channels: Book Publishing Industry ...
Published on July 21, 2023 - 12:22 GMT

Automotive Transmission Oil Filter Market Poised to Reach US$ 3.9 Billion by 2033: Innovative Filters and Accelerated Performance, ...

New York, July 21, 2023 (GLOBE NEWSWIRE) -- The Global Automotive Transmission Oil Filter Market is expected to reach US$ 3.9 Billion by 2033, growing at a CAGR of 4.5% from 2023 to 2033. The market is being driven by the increasing demand for passenger …

Distribution channels: Book Publishing Industry ...
Published on July 21, 2023 - 12:22 GMT

Summary of opinion: Abrysvo,Respiratory syncytial virus vaccines, 20/07/2023, Positive

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Abrysvo, intended for the prevention of lower respiratory tract (LRT) …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:22 GMT

Summary of opinion: Olumiant,baricitinib, 20/07/2023, Positive

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Olumiant to include the treatment of juvenile idiopathic …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:22 GMT

Summary of opinion: Krazati,adagrasib, 20/07/2023, Negative

The European Medicines Agency has recommended the refusal of the conditional marketing authorisation for Krazati, a medicine intended for treating advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation. The Agency issued its opinion on 20 July …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:22 GMT

Summary of opinion: Keytruda,pembrolizumab, 20/07/2023, Positive

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Keytruda. The marketing authorisation holder for this …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:22 GMT

Summary of opinion: Tevimbra,tislelizumab, 20/07/2023, Positive

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Tevimbra1 intended for the treatment of oesophageal squamous cell …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:22 GMT

Summary of opinion: Tepkinly,epcoritamab, 20/07/2023, Positive

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional1 marketing authorisation for the medicinal product Tepkinly2, intended for the treatment of diffuse large B‑ …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:22 GMT

Summary of opinion: Ervebo,Ebola Zaire Vaccine (rVSV∆G-ZEBOV-GP, live), 20/07/2023, Positive

Summary of opinion: Ervebo,Ebola Zaire Vaccine (rVSV∆G-ZEBOV-GP, live), 20/07/2023, Positive

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:21 GMT

Summary of opinion: Bylvay,odevixibat, 20/07/2023, Positive

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Bylvay. The marketing authorisation holder for this medicinal …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:21 GMT

Summary of opinion: Enrylaze,crisantaspase, 20/07/2023, Positive

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Enrylaze, intended for the treatment of acute lymphoblastic leukaemia ( …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:21 GMT

Summary of opinion: Orserdu,elacestrant, 20/07/2023, Positive

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Orserdu, intended for the treatment of ER-positive, HER2-negative breast …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:21 GMT

Summary of opinion: Litfulo,ritlecitinib, 20/07/2023, Positive

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Litfulo, intended for the treatment of alopecia areata (AA). The …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:21 GMT

Summary of opinion: Talvey,talquetamab, 20/07/2023, Positive

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional1 marketing authorisation for the medicinal product Talvey2, intended for the treatment of multiple myeloma. …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:21 GMT

Summary of opinion: Lyfnua,gefapixant, 20/07/2023, Positive

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Lyfnua, intended for the treatment of refractory or unexplained chronic …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:21 GMT

Summary of opinion: Tyruko,natalizumab, 20/07/2023, Positive

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Tyruko, intended for the treatment of multiple sclerosis. The applicant …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:20 GMT

Summary of opinion: Apretude,cabotegravir, 20/07/2023, Positive

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Apretude, intended for prevention of sexually acquired HIV-1 in …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:20 GMT

Summary of opinion: Spikevax (previously COVID-19 Vaccine Moderna),elasomeran,imelasomeran and elasomeran,davesomeran and ...

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Spikevax. The marketing authorisation holder for this …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:20 GMT

Summary of opinion: Degarelix Accord,degarelix acetate, 20/07/2023, Positive

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Degarelix Accord, intended for the treatment of hormone dependent …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on July 21, 2023 - 12:20 GMT

Summary of opinion: Yesafili,aflibercept, 20/07/2023, Positive

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Yesafili, intended for the treatment of neovascular (wet) age-related …

Distribution channels: Healthcare & Pharmaceuticals Industry

Previous 25 26 27 28 29 30 31 32 33 34 35 Next

Previous Day 2023 Calendar Next Day